Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
13.38 USD | +3.60% | +2.78% | -11.13% |
05-14 | Oppenheimer Lowers UroGen Pharma Price Target to $32 From $34, Maintains Outperform Rating | MT |
05-13 | Transcript : UroGen Pharma Ltd., Q1 2024 Earnings Call, May 13, 2024 |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.13% | 466M | |
+7.89% | 115B | |
+13.07% | 107B | |
-12.99% | 22.31B | |
-3.99% | 21.6B | |
-6.20% | 18.23B | |
-39.93% | 17.62B | |
+7.26% | 14.26B | |
+32.79% | 12.37B | |
-28.39% | 8.28B |
- Stock Market
- Equities
- URGN Stock
- News UroGen Pharma Ltd.
- Transcript : UroGen Pharma Ltd. - Special Call